MARGINAL ZONE LYMPHOMA
Clinical trials for MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR-T therapy takes on tough blood cancers
Disease control Not yet recruitingThis early study is testing a new treatment called 19UCART, which uses specially engineered immune cells to target and kill cancer cells in people with B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to standard treatments or have returned. The…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
Experimental immune cell cocktail targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, pomalidomide and obinutuzumab, in people with slow-growing lymphomas (like follicular lymphoma) that have returned or not responded to prior therapy. The first part finds the safest dose, and the second part checks how well the combina…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New combo aims to control Slow-Growing blood cancer without chemo
Disease control Not yet recruitingThis study tests a three-drug combination (pomalidomide, an anti-CD20 antibody, and prednisone) as a first treatment for people with slow-growing B-cell lymphomas. About 30 adults who have not had prior treatment will receive six cycles of the drugs, followed by two years of main…
Matched conditions: MARGINAL ZONE LYMPHOMA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug duo targets hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC